This data not only indicated the effect of Ikaros activator on their expression, but also suggested that Ikaros-induced changes of c-MYC/MYCBP2 expression is at least partially responsible for the success of CK2 inhibitors in ALL therapy. The gene discussed is MYCBP2; the disease is acute lymphoblastic leukemia.